Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Commerce, Management, Tourism And Services
Accounting, Auditing And Accountability
Accounting Theory And Standards
Patient-reported Disability Progression Outcomes Among Patients With Multiple Sclerosis: Results Of An Outcomes-based Agreement.

Home
Research Domains
Commerce, Management, Tourism And Services
Accounting, Auditing And Accountability
Accounting Theory And Standards
Patient-reported Disability Progression Outcomes Among Patients With Multiple Sclerosis: Results Of An Outcomes-based Agreement.

Related Experiment Video

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Patient-reported disability progression outcomes among patients with multiple sclerosis: Results of an outcomes-based agreement.

Elizabeth C S Swart¹, Samuel K Peasah¹, Jacqueline Alderson²

¹Value-Based Pharmacy Initiatives, UPMC Center for High-Value Health Care, Pittsburgh, PA.

Journal of Managed Care & Specialty Pharmacy

|October 29, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Outcomes-based agreements (OBAs) can effectively track patient outcomes in multiple sclerosis (MS). This study found disability progression occurred in 11% of patients, with higher rates in those taking interferon β-1a compared to dimethyl fumarate.

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

Related Experiment Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis

Published on: January 29, 2016

Area of Science:

Health economics
Pharmacoeconomics
Real-world evidence

Background:

Outcomes-based agreements (OBAs) link medication payment to patient health outcomes, aligning with the shift to value-based care.
Multiple sclerosis (MS) is a key area for OBAs due to high medication costs and available treatments.

Purpose of the Study:

To evaluate an outcomes-based agreement for patients with multiple sclerosis (MS) using real-world data.
To assess disability progression in patients taking interferon β-1a or dimethyl fumarate under an OBA.

Main Methods:

A prospective, real-world analysis included commercial or health insurance exchange members with MS.
Disability progression was measured using patient-reported outcomes (PROs) via the patient-determined disease steps (PDDS) tool.

PDDS scores were collected at baseline and follow-up (90-180 days) to identify disability progression.

Main Results:

Of 184 eligible patients (107 on dimethyl fumarate, 77 on interferon β-1a), 21 (11%) experienced confirmed disability progression.
Dimethyl fumarate cohort: 5.6% (6/107) showed progression.
Interferon β-1a cohort: 19.5% (15/77) showed progression.

Conclusions:

Patient-reported outcomes, such as disability progression, can be successfully operationalized within innovative outcomes-based agreements.
The study demonstrates the feasibility of using OBAs to monitor treatment effectiveness in MS.